Anti-TIF1-γ-associated dermatomyositis associated with recurrent metastatic triple-negative breast cancer: Dramatic clinical response to sacituzumab govitecan

被引：0
|
作者：
Wang, Wei-Yao [1 ,2 ]
Lee, Chin-Yu [1 ,2 ]
Hu, Stephen Chu-Sung [1 ,2 ,3 ]
机构：
[1] Kaohsiung Med Univ Hosp, Dept Dermatol, 100,Tzyou 1st Rd, Kaohsiung 807, Taiwan
[2] Kaohsiung Med Univ, Coll Med, Dept Dermatol, Kaohsiung, Taiwan
[3] Kaohsiung Municipal Siaogang Hosp, Dept Dermatol, Kaohsiung, Taiwan
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2024年 / 22卷 / 07期
关键词：
Anti-transcriptional intermediary factor 1 gamma antibody; breast cancer; dermatomyositis; paraneoplastic syndrome; sacituzumab govitecan; AUTOANTIBODIES;
D O I：
10.1111/ddg.15399
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：1008 / 1011
页数：4
相关论文
共 50 条
  • [21] Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
    Chen, Jigang
    Han, Mingyang
    Liu, Aihua
    Shi, Bo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
    Bardia, Aditya
    Hurvitz, Sara A.
    Rugo, Hope S.
    Brufsky, Adam
    Cortes, Javier
    Loibl, Sibylle
    Piccart, M.
    Cowden, Janice
    Spears, Patty
    Carey, Lisa A.
    FUTURE ONCOLOGY, 2021, 17 (30) : 3911 - 3924
  • [23] Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study
    Carrion-Madronal, Isabel Maria
    Diaz-Acedo, Rocio
    Lora-Escobar, Santiago Jose
    Naranjo-Llamas, Eloisa
    Jaramillo-Ruiz, Didiana
    Artacho-Criado, Silvia
    Prado-Mel, Elena
    FUTURE ONCOLOGY, 2024, 20 (33) : 2565 - 2572
  • [24] Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
    Weiss, Jennifer
    Glode, Ashley
    Messersmith, Wells A.
    Diamond, Jennifer
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 673 - 679
  • [25] Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
    Sathe, Abhishek G.
    Singh, Indrajeet
    Singh, Pratap
    Diderichsen, Paul M.
    Wang, Xiaohui
    Chang, Peter
    Taqui, Atiya
    Phan, See
    Girish, Sandhya
    Othman, Ahmed A.
    CLINICAL PHARMACOKINETICS, 2024, 63 (05) : 669 - 681
  • [26] Sacituzumab govitecan-a new therapy for patients with triple-negative breast cancer
    Pogoda, Katarzyna
    Jagiello-Gruszfeld, Agnieszka
    Niwinska, Anna
    Nowecki, Zbigniew
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (01): : 43 - 49
  • [27] Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back
    Rossi, Valentina
    Turati, Alessandra
    Rosato, Antonio
    Carpanese, Debora
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [28] Revolutionizing triple-negative metastatic breast cancer treatment: sacituzumab Govitecan's role in advancing chemotherapy
    Qureshi, Zaheer
    Jamil, Abdur
    Altaf, Faryal
    Siddique, Rimsha
    Fatima, Eeshal
    Dost, Sara
    Zelkowitz, Richard Scott
    Shah, Shivendra
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (09): : 5314 - 5319
  • [29] Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
    Abhishek G. Sathe
    Indrajeet Singh
    Pratap Singh
    Paul M. Diderichsen
    Xiaohui Wang
    Peter Chang
    Atiya Taqui
    See Phan
    Sandhya Girish
    Ahmed A. Othman
    Clinical Pharmacokinetics, 2024, 63 : 669 - 681
  • [30] Considerable Improvement in Overall Survival through Sacituzumab-Govitecan in metastatic triple-negative Breast Cancer
    Pervan, Mascha
    Krawczyk, Natalia
    Hanker, Lars
    Bundgen, Nana
    Rody, Achim
    Banys-Paluchowski, M.
    ONKOLOGE, 2021, 27 (11): : 1131 - 1136
12345